Adult

Living Life

by

By Jack Coates

In May 2001, I was diagnosed with medulloblastoma. I was 19 years old and had just finished my freshman year at Johnson & Wales University in Rhode Island.

Medulloblastoma is a cancer that affects the brain and the spine. I had three surgeries, 52 weeks of chemo, and six weeks of radiation. I spent a year and two months in the hospital and went from 217 pounds to 97. I was scared. I was asking God: “Why?  Why did it have to happen to me?” It was shocking. Many things went through my mind.

Read more

Clinical Trials Paving the Way for Improved Vulvar Cancer Treatment

by

Cancers of the vulva – the external portion of the female genitals – are diagnosed in approximately 4,700 women in the United States each year. While many patients can be cured by a combination of surgery, chemotherapy, and radiation therapy, others – particularly those whose cancer has metastasized to other parts of the body – often don’t fare as well.

As one of the rarer forms of gynecologic cancer, vulvar cancer hasn’t attracted as much research funding as other forms. Still, several efforts are under way to make treatment options more effective, according to Neil Horowitz, MD, a vulvar cancer expert at the Susan F. Smith Center for Women’s Cancers at Dana-Farber.

Read more

Colorectal Cancer: Five Things You Need to Know

by

Colorectal cancer is the fourth most common cancer in the U.S., with about 143,000 new patients diagnosed last year. But thanks to increased awareness about screenings, the death rate from colorectal cancer has been dropping for more than 20 years.

Jeffrey Meyerhardt, MD, MPH
Jeffrey Meyerhardt, MD, MPH

“For the most part, colorectal cancer is a curable and preventable disease,” says Jeffrey Meyerhardt, MD, MPH, clinical director of the Dana-Farber Gastrointestinal Cancer Treatment Center. “We have very good data that shows screening prevents disease and saves lives.”

With March marking Colorectal Cancer Awareness Month, here are the answers to some key questions about the disease:

Read more

A History of Multiple Myeloma Advances

by

Not long ago, a diagnosis of multiple myeloma — a cancer of the bone marrow — carried with it a very poor prognosis, with median survival estimates of just two to three years. Now, thanks in large part to research and treatment advances at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), this disease is for many patients a chronic, and more manageable disease, with prognosis now improved to median survivals of seven to ten years.

Here is a look at how DF/BWCC physician-scientists and patients have helped lead the way toward improved treatment for multiple myeloma over the past three decades.

Read more

Progress and Promise in Prostate Cancer Research

by

In prostate cancer – the most common cancer in men aside from skin cancer – scientists are working to answer some of the most basic questions about the disease while developing an array of new treatments.

Using the prostate-specific antigen (PSA) blood test, doctors are often able to detect prostate cancer at an early stage. But it remains difficult to determine which prostate cancers are likely to spread – and therefore require aggressive treatment – and which are either idle or slow-growing, and can be dealt with by “observation or active surveillance.” This uncertainty could result in unnecessary treatment for some patients.

Read more

How Does Testicular Cancer Affect Fertility and Sexuality?

by

Testicular cancer, which is most often diagnosed in men between the ages of 20 and 34, often creates major concerns about fertility and sexuality for people of all ages. While treatment will require removal of the affected testicle, someone can still retain full sexual function after surgery. Likewise, while treatment can affect fertility, there are … Read more

Five Things You Need to Know About Donating Bone Marrow

by

Medically reviewed by Joseph H. Antin, MD

Thousands of people who face life-threatening blood diseases, such as leukemia, lymphoma and multiple myeloma, require treatment with a stem cell transplantation (also referred to as a bone marrow transplantation). For many patients, the best treatment approach is an allogeneic transplant, in which healthy stem cells are collected from another person. The stem cell donor is selected based on how well his or her Human Leukocyte Antigen (HLA) markers match that of the patient.

Although a person’s HLA type is inherited from his or her parents, the likelihood of finding an HLA match with a family member is only 25 to 30 percent.

“Most people don’t have matched donors in the family, and if we’re going to provide stem cell transplants to cure these otherwise incurable diseases, we need to have a donor,” says Joseph Antin, MD, chief of the Dana-Farber/Brigham and Women’s Cancer Center Adult Stem Cell Transplantation Program.

Read more

How to Ease Chemotherapy Side Effects with Food

by

Cancer treatments, especially chemotherapy, can make eating well and enjoying food a challenge for many patients. Food may start to taste strange, appetite may diminish, and other symptoms, such as fatigue, bowel changes, nausea, and mouth sores, may make finding nutritious, delicious foods difficult.

“During chemotherapy, it’s very common for patients to not feel like eating, for appetite to be low, or the taste of food to be off,” says Dana-Farber nutritionist Stacy Kennedy, MPH, RD, who stresses the importance of maintaining a healthy diet to manage symptoms. In the video below, Kennedy explains how to combat symptoms by incorporating tart or sour flavors, eating small and frequent meals, and staying hydrated:

Read more

New Strategies in Treating Kidney Cancer

by

Though quite curable when diagnosed early, kidney cancer in advanced stages can become a stubborn disease.

However, the outlook for patients with metastatic kidney cancer has brightened in the past several years. Oncologists have added to their arsenal a number of designer drugs that attack molecular targets – genetic abnormalities that drive tumors – with high specificity.

Read more

New Findings May Change Treatment of Advanced Prostate Cancer

by

For about 70 years, the standard treatment for patients with advanced prostate cancer was drugs that blocked male hormones feeding the tumor. If that stopped working and the disease progressed, oncologists turned to chemotherapy to kill the cancer cells.

This timetable is about to change. Results of a clinical trial led by a Dana-Farber researcher revealed that such patients lived longer if started on both a hormone blocker and a chemotherapy drug at the same time. The government-sponsored trial found that 69 percent of men receiving both treatments were alive at three years, compared with 52.5 percent of men who initially got just the hormone blocker. The advantage was so striking – especially for patients with greater degrees of cancer spread – that the National Cancer Institute publicized the findings ahead of schedule to alert doctors and patients.

“The results of this study are practice-changing for some patients,” says Christopher Sweeney, MBBS, clinical director of Dana-Farber’s Lank Center for Genitourinary Cancer, who headed the trial. We asked him to explain:

Read more

Ask the Expert: Questions and Answers About Breast Cancer Treatment

by

Dana-Farber Cancer Institute’s Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH recently partnered with CancerConnect to answer questions about breast cancer therapies. Burstein and Mayer are breast oncologists in the Center for Breast Oncology at Dana-Farber’s Susan F. Smith Center for Women’s Cancers.

 

Q: What medications are helpful for depression after breast cancer treatment and while taking tamoxifen?

Read more